Study examines characteristics of vision loss after subretinal hemorrhage in wet AMD
Click Here to Manage Email Alerts
Patients with neovascular age-related macular degeneration who experienced catastrophic vision loss after subretinal hemorrhage were linked to longer anti-VEGF treatment duration and shorter time from prior injection.
At the American Society of Retina Specialists annual meeting, Eric W. Schneider, MD, presented study data examining the baseline characteristics that could predict catastrophic vision loss after the development of subretinal hemorrhage following anti-VEGF treatment.
“There was no association seen with anticoagulant or antiplatelet use, systemic hypertension or evidence of [choroidal neovascularization] activity as gauged by the presence of intra- or subretinal fluid on OCT,” Schneider said.
The study was conducted using electronic health records from a single practice focused on patients who experienced a significant drop in visual acuity —a loss of more than 25 letters — after subretinal hemorrhage compared with the baseline visit.
Forty-two eyes of 40 patients were included in the study, with 45.2% experiencing catastrophic vision loss.
The study found that a longer duration of anti-VEGF therapy and presentation prior to typical re-treatment intervals were significantly associated with a higher risk for decrease in visual acuity.
“Subretinal hemorrhage is a relatively uncommon occurrence in anti-VEGF-treated patients with neovascular AMD, with an incidence ranging from 1.5 to 4.5 per 1,000 patients per year,” Schneider said.
However, it is an important consideration because it can cause poor visual outcomes, including low final visual acuity, he said.
A multicenter study is underway to confirm these findings, Schneider said.
Collapse
Schneider E, et al. Baseline characteristics associated with catastrophic vision loss due to subretinal hemorrhage in patients undergoing treatment for neovascular macular degeneration. Presented at: American Society of Retina Specialists annual meeting; July 17-20, 2024; Stockholm.
Click Here to Manage Email Alerts